Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7371309 | 1.00 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL25886436 | 0.88 | HCAR2 (0.36) | ALDH1A1TSHRHPGDHCAR2NOD1 | |
| SCHEMBL14174568 | 0.86 | ALDH1A1 (0.47) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| Hydrochloric Acid SCHEMBL3363507 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| Hydrochloric Acid SCHEMBL216129 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| Hydrochloric Acid SCHEMBL12478441 | 0.84 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| Hydrochloric Acid SCHEMBL28713628 | 0.84 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| Hydrochloric Acid SCHEMBL5487402 | 0.84 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| Hydrochloric Acid SCHEMBL7374816 | 0.84 | ALDH1A1 (0.41) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL2734881 | 0.83 | ALDH1A1 (0.52) | ALDH1A1ATMTSHRHPGDHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2813241-B1 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9403868-B2 | Crystalline tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160213610-A1 | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | ONYX THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9295708-B2 | Modified release formulations for oprozomib | ONYX THERAPEUTICS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-03-24 | — | — | US | disclosed |
| WO-2016011088-A2 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | CENTRAX INTERNATIONAL, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-9205125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1948678-B1 | Compounds for enzyme inhibition | ONYX THERAPEUTICS INC (US) | 2013-05-01 | — | — | EP | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120088903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108172-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | ALDH1A1 3041/4885ATM 4793/4885TSHR 3077/4885 |
| US-20160213610-A1 | MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB | OPRL1, OPRM1, OPRK1 | ALDH1A1 3123/4885ATM 4246/4885TSHR 1863/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | ALDH1A1 3650/4885ATM 4632/4885TSHR 2821/4885 |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | ALDH1A1 3164/4885ATM 4834/4885TSHR 2901/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | ALDH1A1 3059/4885ATM 4734/4885TSHR 2765/4885 |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | ALDH1A1 3164/4885ATM 4834/4885TSHR 2901/4885 |
| US-20170158734-A1 | EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION | PSMD10, PSMC1, PSMB10 | ALDH1A1 1707/4885ATM 3065/4885TSHR 4650/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | ALDH1A1 3041/4885ATM 4793/4885TSHR 3077/4885 |
| US-20100240903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | ALDH1A1 2956/4885ATM 4641/4885TSHR 3868/4885 |
| US-20120077855-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | CTSC, PEPD, PREP | ALDH1A1 3205/4885ATM 4512/4885TSHR 3792/4885 |
| US-20120088903-A1 | CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTSC, PEPD | ALDH1A1 2956/4885ATM 4641/4885TSHR 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.